313 related articles for article (PubMed ID: 27379693)
1. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
2. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Wendtner CM
Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
[No Abstract] [Full Text] [Related]
3. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
4. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
5. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
6. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
[No Abstract] [Full Text] [Related]
7. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
[TBL] [Abstract][Full Text] [Related]
8. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
9. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
10. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
[TBL] [Abstract][Full Text] [Related]
11. Novel agents versus chemotherapy as frontline treatment of CLL.
Piggin A; Bayly E; Tam CS
Leuk Lymphoma; 2017 Jun; 58(6):1320-1324. PubMed ID: 28271950
[TBL] [Abstract][Full Text] [Related]
12. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
13. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Jain N; O'Brien S
Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
15. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
UK CLL Forum
Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
[No Abstract] [Full Text] [Related]
17. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
[TBL] [Abstract][Full Text] [Related]
18. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
Burger JA
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
[No Abstract] [Full Text] [Related]
19. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
[No Abstract] [Full Text] [Related]
20. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
